Livdelzi (seladelpar)

Livdelzi (seladelpar) is a prescription medicine for the treatment of adults with primary biliary cholangitis (PBC). It can be used in combination with ursodeoxycholic acid (UDCA) for patients who have an inadequate response to UDCA, or as monotherapy in patients who cannot tolerate UDCA 1.

Livdelzi (seladelpar) is currently only approved in the USA 2.

Categories: ,

What is Livdelzi (seladelpar) for?

Livdelzi (seladelpar) is indicated for the treatment of primary biliary cholangitis (PBC) in adult patients. It can be used in combination with ursodeoxycholic acid (UDCA) for patients who have an inadequate response to UDCA, or as monotherapy in patients who cannot tolerate UDCA [1].

Livdelzi (seladelpar) is available as capsules (10 mg) [1].

How does Livdelzi (seladelpar) work?

Livdelzi (seladelpar) activates a protein called PPAR-delta (δ), which may help reduce bile acid production, though the exact way it benefits patients with primary biliary cholangitis (PBC) is unclear. Research suggests that seladelpar lowers bile acid levels by decreasing the activity of an enzyme called CYP7A1 through a process involving the protein FGF21 [1].

Where has Livdelzi (seladelpar) been approved?

Livdelzi (seladelpar) is currently only approved by the FDA in the USA [2].